The discrepancy in findings could be due to the use of different GLP-1 RAs, as a class effect has been previously suggested, different participant characteristics that influence effectiveness of GLP-1 RAs, such as type 2 diabetes or overweight, or study settings such as duration of treatment and additional co-medication. Here, GCG is linked to type 2 diabetes mellitus.